The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …

Angiogenesis is a crucial event in tumor development and progression, occurring by
different mechanisms and it is driven by pro-and anti-angiogenic molecules. Pancreatic …

BACKGROUND Hypertension (HTN) is an established class effect of vascular endothelial
growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in …

Patients with pancreatic cancer have a poor prognosis with a median survival of 4-6 mo and
a 5-year survival of less than 5%. Despite therapy with gemcitabine, patient survival does …

Background Rapid progress over the last decade has added numerous agents targeting
specific cellular signaling pathways to the treatment armamentarium for advanced cancer …

Background: Cardio-oncology aims to mitigate adverse cardiovascular manifestations in
cancer survivors, but treatment-induced hypertension or aggravated hypertension has …

Background Bevacizumab is a beneficial therapy in several advanced cancer types.
Predictive biomarkers to better understand which patients are destined to benefit or …

Angiotensin II receptor blockers (ARBs) are anti-hypertensive drugs that competitively inhibit
the binding of angiotensin II to its receptor, resulting in blood vessel dilation and the …

Recognition of the molecular heterogeneity of colorectal cancer (CRC) has led to the
classification of CRC based on a variety of clinical and molecular characteristics. Although …

Introduction: About one third of patients affected with thyroid cancer present with recurrent
disease. Unresectability, advanced disease and radioiodine refractoriness are considered …